Opendata, web and dolomites

PML-THERAPY SIGNED

HARNESSING PML NUCLEAR BODIES FOR LEUKAEMIA THERAPY

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 PML-THERAPY project word cloud

Explore the words cloud of the PML-THERAPY project. It provides you a very rough idea of what is the project "PML-THERAPY" about.

pressure    hif1a    inactivated    modulation    basal    sumos    innovative    libraries    combination    homeostasis    ptm    trioxide    underlying    proteins    mechanistically    rara    patients    acute    nuclear    arsenic    expressing    pml    retinoic    broad    models    contributes    lost    disruption    exploring    myeloid    leukaemia    mechanism    malignancies    restore    leukaemias    exploration    mutant    absolutely    unmet    incompletely    p53    mice    integrate    cancers    allele    loose    stress    jak2    modulating    oxidative    tax    mechanistic    npmc    modifications    organizes    normal    downstream    oncogenesis    critically    expression    responsive    bind    controls    client    signalling    found    translational    biogenesis    repertoire    interferon    therapeutic    conjugation    somehow    apl    series    dependent    bodies    multiple    generate    domains    blunts    viral    explore    resistance    dissect    senescence    sensitive    sensor    vivo    therapy    acid    nbs    cure    physiologically    infections    degradation    ifn    sumoylated    drugs    cancer    behaves    bases    therapeutically    elaborate    medical    restoration    knock    first    post    rb    nb    recruit    selective    promyelocytic    manner    screen    needs    strategies    regulated    redox    chemical    checkpoint    ra    activates   

Project "PML-THERAPY" data sheet

The following table provides information about the project.

Coordinator
INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE 

Organization address
address: RUE DE TOLBIAC 101
city: PARIS
postcode: 75654
website: www.inserm.fr

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country France [FR]
 Total cost 2˙500˙000 €
 EC max contribution 2˙500˙000 € (100%)
 Programme 1. H2020-EU.1.1. (EXCELLENT SCIENCE - European Research Council (ERC))
 Code Call ERC-2017-ADG
 Funding Scheme ERC-ADG
 Starting year 2019
 Duration (year-month-day) from 2019-04-01   to  2024-03-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE FR (PARIS) coordinator 2˙400˙000.00
2    American University of Beirut LB (BEIRUT) participant 100˙000.00

Map

 Project objective

In acute promyelocytic leukaemia (APL), retinoic acid (RA) and Arsenic trioxide (As) bind PML/RARA and promote its degradation. Exploring the mechanistic bases for APL response to the RA/As combination, we found that upon PML/RARA degradation the normal PML allele activates a PML/P53 checkpoint absolutely required for APL cure in mice or patients. Physiologically, PML behaves as an oxidative stress sensor and contributes to redox homeostasis. PML organizes nuclear bodies (NBs), domains that recruit multiple client proteins and may facilitate their post-translational modifications (PTM), particularly conjugation of SUMOs. This somehow controls multiple downstream pathways such as P53, but also RB, HIF1A or interferon (IFN). In APL, NB-disruption blunts P53-driven senescence, contributing to oncogenesis and therapy resistance. Critically, PML expression and/or NB-formation are lost upon many viral infections or during cancer development. The mechanism(s) underlying the selective pressure to loose PML expression in multiple cancers remains incompletely understood. Our aim is to mechanistically dissect PML signalling in vivo and therapeutically restore it in malignancies where it is inactivated. We first propose a broad exploration of PML in mice to identify basal and stress-induced PML PTM and identify the repertoire of proteins sumoylated in a PML- dependent manner. We will generate a series of PML knock-in mutant mice and analyse their P53- regulated redox homeostasis. We will mechanistically explore PML/P53-driven senescence in three leukaemia models where we have evidence for basal or therapy-responsive NB-modulation: acute myeloid leukaemia expressing NPMc and IFN-sensitive Tax- or JAK2-driven leukaemias. We will screen chemical libraries for drugs modulating PML expression and/or NB biogenesis. Finally, we will integrate our findings to elaborate innovative therapeutic strategies based on restoration of the PML/P53 checkpoint in leukaemia with unmet medical needs

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "PML-THERAPY" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "PML-THERAPY" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.1.)

CerQuS (2019)

Certified Quantum Security

Read More  

PANTROP (2019)

Biodiversity and recovery of forest in tropical landscapes

Read More  

EnTER (2020)

Enhanced Mass Transport in Electrochemical Systems for Renewable Fuels and Clean Water

Read More